- Home
- IMMP vs RDIB Comparison
IMMP vs RDIB Comparison
Compare IMMP & RDIB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- IMMP
- RDIB
- Stock Information
- Founded
- IMMP 1987
- RDIB 1937
- Country
- IMMP Australia
- RDIB United States
- Employees
- IMMP N/A
- RDIB N/A
- Industry
- IMMP Biotechnology: Pharmaceutical Preparations
- RDIB Movies/Entertainment
- Sector
- IMMP Health Care
- RDIB Consumer Discretionary
- Exchange
- IMMP Nasdaq
- RDIB Nasdaq
- Market Cap
- IMMP 251.8M
- RDIB 279.6M
- IPO Year
- IMMP N/A
- RDIB N/A
- Fundamental
- Price
- IMMP $1.68
- RDIB $11.78
- Analyst Decision
- IMMP Buy
- RDIB
- Analyst Count
- IMMP 1
- RDIB 0
- Target Price
- IMMP $7.00
- RDIB N/A
- AVG Volume (30 Days)
- IMMP 88.5K
- RDIB 6.3K
- Earning Date
- IMMP 10-21-2025
- RDIB 11-13-2025
- Dividend Yield
- IMMP N/A
- RDIB N/A
- EPS Growth
- IMMP N/A
- RDIB N/A
- EPS
- IMMP N/A
- RDIB N/A
- Revenue
- IMMP $3,306,742.00
- RDIB $219,213,000.00
- Revenue This Year
- IMMP N/A
- RDIB $5.21
- Revenue Next Year
- IMMP $725.37
- RDIB $11.45
- P/E Ratio
- IMMP N/A
- RDIB N/A
- Revenue Growth
- IMMP 31.28
- RDIB 7.59
- 52 Week Low
- IMMP $1.32
- RDIB $5.78
- 52 Week High
- IMMP $2.71
- RDIB $14.95
- Technical
- Relative Strength Index (RSI)
- IMMP 50.03
- RDIB 47.96
- Support Level
- IMMP $1.60
- RDIB $10.70
- Resistance Level
- IMMP $1.76
- RDIB $12.60
- Average True Range (ATR)
- IMMP 0.06
- RDIB 0.87
- MACD
- IMMP 0.01
- RDIB -0.15
- Stochastic Oscillator
- IMMP 52.94
- RDIB 51.73
About IMMP Immutep Limited
Immutep Ltd is a globally active biotechnology company developing immunotherapy products for cancer and autoimmune diseases. Its main product is IMP321, which involves clinical development for the treatment of cancer indications. The company is also focused on the development of other products, which include IMP701, which is a blocking anti-LAG-3 antibody for cancer and is in Phase I of its clinical trials, and CVac, which is a personalized immunocellular therapeutic investigated for the treatment of epithelial cancer. Geographically all the business activity of the firm is functioned through the region of Australia.
About RDIB Reading International Inc Class B
Reading International Inc is a diversified company, engaged in the development, ownership, and operation of multiplex cinemas and retail and commercial real estate in the United States, Australia, and New Zealand. It operates through two segments: the Cinema segment includes Reading Cinemas, Angelika Film Center, Consolidated Theatres, and City Cinemas; the Real Estate segment includes real estate development and the rental or licensing of retail, commercial and live theater assets.